[HTML][HTML] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
A Patnaik, GJ Weiss, DW Rasco, L Blaydorn… - Cancer chemotherapy …, 2022 - Springer
Purpose New immuno-oncology therapies targeting programmed cell death receptor 1 (PD-
1) have improved patient outcomes in a broad range of cancers. The objective of this …
1) have improved patient outcomes in a broad range of cancers. The objective of this …
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
P Amita, GJ Weiss, DW Rasco, B Lisa… - Cancer …, 2022 - search.proquest.com
Purpose New immuno-oncology therapies targeting programmed cell death receptor 1 (PD-
1) have improved patient outcomes in a broad range of cancers. The objective of this …
1) have improved patient outcomes in a broad range of cancers. The objective of this …
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
A Patnaik, GJ Weiss, DW Rasco, L Blaydorn… - Cancer …, 2021 - europepmc.org
Purpose New immuno-oncology therapies targeting programmed cell death receptor 1 (PD-
1) have improved patient outcomes in a broad range of cancers. The objective of this …
1) have improved patient outcomes in a broad range of cancers. The objective of this …
[HTML][HTML] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
A Patnaik, GJ Weiss, DW Rasco… - Cancer …, 2022 - ncbi.nlm.nih.gov
Purpose New immuno-oncology therapies targeting programmed cell death receptor 1 (PD-
1) have improved patient outcomes in a broad range of cancers. The objective of this …
1) have improved patient outcomes in a broad range of cancers. The objective of this …
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial
A Patnaik, GJ Weiss, DW Rasco… - Cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose New immuno-oncology therapies targeting programmed cell death receptor 1 (PD-
1) have improved patient outcomes in a broad range of cancers. The objective of this …
1) have improved patient outcomes in a broad range of cancers. The objective of this …
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial.
A Patnaik, GJ Weiss, DW Rasco… - Cancer …, 2022 - search.ebscohost.com
Purpose: New immuno-oncology therapies targeting programmed cell death receptor 1 (PD-
1) have improved patient outcomes in a broad range of cancers. The objective of this …
1) have improved patient outcomes in a broad range of cancers. The objective of this …